GYRE THERAPEUTICS, INC. (GYRE) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 16 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026after close 36 8-K
Q2 FY2026Fri, Aug 7, 2026before open 38 8-K
Q1 FY2026Wed, May 6, 2026after close 36 8-K
Q4 FY2025Wed, Mar 11, 2026after close 70 8-K
Q3 FY2025Thu, Nov 6, 2025after close 37 8-K
Q2 FY2025Mon, Aug 11, 2025after close 42 8-K
Q1 FY2025Thu, May 8, 2025after close 38 8-K
Q4 FY2024Mon, Mar 17, 2025after close 76 8-K

What they guided beta

Q3 FY2026 "Exhibit 99.1 Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, November 5, 2026 -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), a U.S. biopharmaceutical company with research operations and commercial business in China to advance global development of protein degrader therapeutics, today announced financial results for the third quarter ended September 30, 2026, and pro" exhibit
Q3 FY2026 "Meanwhile, after recently completing an onsite inspection by China’s National Medical Products Administration, or NMPA, we continue to prepare for the China NMPA decision on F351 for CHB-induced liver fibrosis, which we anticipate launching, if approved, sometime in the first half of 2027." exhibit
Q3 FY2026 "We anticipate Phase 1 dose-escalation data to be available in the second half of 2027." exhibit
Q3 FY2026 "Dual-degrader programs (next-generation targeted protein degraders) Gyre expects to submit Investigational New Drug (IND) applications and initiate Phase 1 clinical trials, upon regulatory approval of IND applications, in the United States and/or China around mid-2027 for CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications, and CG620953, a TYK2-JAK1 dual degrader for autoimmune diseases." exhibit
Q3 FY2026 "The $0.3 million, or 2%, decrease was primarily attributable to a $1.1 million reduction in promotional and conference expenses, as certain promotional objectives were achieved during the first half of 2026, resulting in lower spending during the third quarter." exhibit
Q2 FY2026 "Exhibit 99.1 Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China’s CDE in May 2026 SAN DIEGO, August 7, 2026 -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United States and China, today announced financial results for " exhibit
Q2 FY2026 "The final patient is expected to complete the study by the fourth quarter of 2026." exhibit
Q2 FY2026 "Dual-degrader programs, next-generation TPDs: Gyre expects to submit Investigational New Drug (IND) applications in the United States and/or China in the first quarter of 2027 for two additional Cullgen degrader assets: CG923308, a CDK2-Cyclin E dual degrader for solid tumor indications, and CG620953, a TYK2-JAK1 dual degrader for autoimmune diseases." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/GYRE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/GYRE

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

GYRE earnings date badge

HTML

<a href="https://veritasdata.dev/company/GYRE/"><img src="https://veritasdata.dev/embed/GYRE.svg" alt="GYRE earnings date" width="240" height="56"></a>

Markdown

[![GYRE earnings date](https://veritasdata.dev/embed/GYRE.svg)](https://veritasdata.dev/company/GYRE/)

Script

<script async src="https://veritasdata.dev/embed/GYRE.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/GYRE"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.